EG24358A - Isoindolin-1-one glucokinase avtivators - Google Patents

Isoindolin-1-one glucokinase avtivators

Info

Publication number
EG24358A
EG24358A EG20011316A EG20011316A EG24358A EG 24358 A EG24358 A EG 24358A EG 20011316 A EG20011316 A EG 20011316A EG 20011316 A EG20011316 A EG 20011316A EG 24358 A EG24358 A EG 24358A
Authority
EG
Egypt
Prior art keywords
isoindolin
glucokinase
avtivators
diabetes
treatment
Prior art date
Application number
EG20011316A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG24358A publication Critical patent/EG24358A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
EG20011316A 2000-12-13 2001-12-10 Isoindolin-1-one glucokinase avtivators EG24358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13

Publications (1)

Publication Number Publication Date
EG24358A true EG24358A (en) 2009-03-04

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20011316A EG24358A (en) 2000-12-13 2001-12-10 Isoindolin-1-one glucokinase avtivators

Country Status (36)

Country Link
US (1) US6482951B2 (zh)
EP (1) EP1349856B1 (zh)
JP (1) JP4021766B2 (zh)
KR (1) KR100520651B1 (zh)
CN (1) CN1247574C (zh)
AT (1) ATE297922T1 (zh)
AU (2) AU2002238415B2 (zh)
BG (1) BG107903A (zh)
BR (1) BR0116169A (zh)
CA (1) CA2430579C (zh)
CY (1) CY1105587T1 (zh)
CZ (1) CZ20031882A3 (zh)
DE (1) DE60111570T2 (zh)
DK (1) DK1349856T3 (zh)
EG (1) EG24358A (zh)
ES (1) ES2243578T3 (zh)
HK (1) HK1063314A1 (zh)
HR (1) HRP20030450B1 (zh)
HU (1) HUP0400587A3 (zh)
IL (2) IL156264A0 (zh)
MA (1) MA26973A1 (zh)
MX (1) MXPA03005170A (zh)
MY (1) MY136741A (zh)
NO (1) NO325810B1 (zh)
NZ (1) NZ526236A (zh)
PA (1) PA8534601A1 (zh)
PE (1) PE20020593A1 (zh)
PL (1) PL366006A1 (zh)
PT (1) PT1349856E (zh)
RS (1) RS50933B (zh)
RU (1) RU2249590C2 (zh)
SI (1) SI1349856T1 (zh)
SK (1) SK8732003A3 (zh)
TW (1) TWI294876B (zh)
UY (1) UY27069A1 (zh)
WO (1) WO2002048106A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
ES2293005T3 (es) 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
JP2007530631A (ja) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
KR20080040046A (ko) * 2005-08-31 2008-05-07 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
WO2007053503A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CA2628259A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
CN101321747A (zh) * 2005-11-01 2008-12-10 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类
JP2009513711A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
US20090005391A1 (en) * 2005-11-03 2009-01-01 Matthew Colin Thor Fyfe Tricyclo Substituted Amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
EA017775B1 (ru) * 2008-01-24 2013-03-29 Мерк Патент Гмбх ПРОИЗВОДНЫЕ β-АМИНОКИСЛОТ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
ME02198B (me) * 2008-04-28 2016-02-20 Kyorin Seiyaku Kk Derivati ciklopentilakrilamida
AU2009246167B2 (en) * 2008-05-16 2013-08-22 Takeda California, Inc. Glucokinase activators
NZ591366A (en) * 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
JP6416230B2 (ja) * 2013-05-27 2018-10-31 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規3,4−ジヒドロ−2h−イソキノリン−1−オン及び2,3−ジヒドロ−イソインドール−1−オン化合物
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
TWI767945B (zh) 2016-10-14 2022-06-21 義大利商Tes製藥(股份)責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU767830B2 (en) 1999-03-29 2003-11-27 F. Hoffmann-La Roche Ag Glucokinase activators
ATE304011T1 (de) 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
ES2230309T3 (es) 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.

Also Published As

Publication number Publication date
BR0116169A (pt) 2003-12-23
NZ526236A (en) 2004-12-24
SI1349856T1 (en) 2005-10-31
DK1349856T3 (da) 2005-10-17
HRP20030450A2 (en) 2005-04-30
US20020082260A1 (en) 2002-06-27
DE60111570D1 (de) 2005-07-21
DE60111570T2 (de) 2006-05-11
US6482951B2 (en) 2002-11-19
NO20032674L (no) 2003-06-12
RU2249590C2 (ru) 2005-04-10
ATE297922T1 (de) 2005-07-15
AU2002238415B2 (en) 2007-01-04
UY27069A1 (es) 2002-07-31
SK8732003A3 (en) 2004-04-06
CA2430579A1 (en) 2002-06-20
KR100520651B1 (ko) 2005-10-11
HUP0400587A2 (hu) 2004-06-28
CN1481382A (zh) 2004-03-10
HRP20030450B1 (en) 2006-02-28
KR20030064817A (ko) 2003-08-02
CA2430579C (en) 2010-01-26
BG107903A (bg) 2004-02-27
PE20020593A1 (es) 2002-07-06
NO20032674D0 (no) 2003-06-12
PL366006A1 (en) 2005-01-24
PT1349856E (pt) 2005-09-30
CN1247574C (zh) 2006-03-29
ES2243578T3 (es) 2005-12-01
HK1063314A1 (en) 2004-12-24
JP4021766B2 (ja) 2007-12-12
HUP0400587A3 (en) 2011-03-28
EP1349856A2 (en) 2003-10-08
PA8534601A1 (es) 2002-08-26
MXPA03005170A (es) 2003-09-22
WO2002048106A3 (en) 2002-11-28
CZ20031882A3 (cs) 2003-12-17
RS50933B (sr) 2010-08-31
MY136741A (en) 2008-11-28
IL156264A0 (en) 2004-01-04
TWI294876B (en) 2008-03-21
AU3841502A (en) 2002-06-24
JP2004521095A (ja) 2004-07-15
WO2002048106A2 (en) 2002-06-20
NO325810B1 (no) 2008-07-21
CY1105587T1 (el) 2010-07-28
YU47703A (sh) 2006-05-25
IL156264A (en) 2010-11-30
MA26973A1 (fr) 2004-12-20
EP1349856B1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MY136926A (en) Glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
JO2180B1 (en) Glucokinase Trans olivine steroids
IL144948A0 (en) Electroactive pore
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
CA2407416A1 (en) Alkynyl phenyl heteroaromatic glucokinase activators
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
RS20050733A (en) Benzo/1,2,5/thiadiazole compounds
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (en) NEW USE OF PRODIGIOSIN FOR THE TREATMENT OF DIABETES MELLITUS
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
MD1919G2 (ro) Remediu medicamentos
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
ZA200107918B (en) The treatment of rubber.